Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: Effects on the very-low-density and high-density lipoprotein particle distribution

Metabolism: Clinical and Experimental

Volumn 51, Issue 1, 2002, Pages 44-51

  Gómez Pérez, Francisco J ^a,b,c   Aguilar Salinas, Carlos A ^a,b,c   Vaázquez Chávez, Cuauhtémoc ^a,b,c   Fanghaänel Salmón, Guillermo ^a,b,c   Gallegos Martínez, José ^a,b,c   Gómez Dóaz, Rita A ^a,b,c   Salinas Orozco, Saul ^a,b,c   Chavira López, Ismael J ^a,b,c   Sánchez Reyes, Leticia ^a,b,c   Torres Acosta, Evelyn M ^a,b,c   Tamez, Ricardo ^a,b,c   López, Angelina ^a,b,c   Guillé, Luz E ^a,b,c   Cesarman, Gabriela ^a,b,c  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b Hospital General de México   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; INSULIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; TROGLITAZONE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CALORIC INTAKE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET SUPPLEMENTATION; DOSE RESPONSE; DROWSINESS; DRUG ACTIVITY; DUODENUM ULCER; EDEMA; FEMALE; FOOD DRUG INTERACTION; HEMOGLOBIN DETERMINATION; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; INSULIN SENSITIVITY; LIPID ANALYSIS; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEAL; METABOLIC DISORDER; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PARALLEL DESIGN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TABLET; VERTIGO;

EID: 0036150157     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.29024     Document Type: Article

References (67)

1. Troglitazone: Antihyperglycemic activity and potential role in the treatment of type 2 diabetes
2. Thiazolidinediones
3. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
4. New oral thiazolidinediones antidiabetic agents act as insulin sensitizers
5. "Glitazones", a prospect for non insulin dependent diabetes
6. Thiazolidinediones: A new class of antidiabetic drug
7. Troglitazone
8. Peroxisome proliferator-activated receptors, orphans with ligands and functions
9. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids
10. A novel N-aryl tyrosine activator of peroxisome proliferator activated receptor gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat
11. Expression of the peroxisome proliferator activated receptor gamma in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
12. Another potential use of troglitazone in non insulin dependent diabetes mellitus
13. Lipotoxic heart disease in obese rats: Implications for human obesity
14. Troglitazone attenuates atherosclerosis in low density lipoprotein receptor -/- mice fed a high fat diet
15. Troglitazone suppresses diabetic nephropathy and cataract formation without decreasing plasma glucose and blood pressure in severy diabetic ZDF rats
16. Effect to troglitazone in insulin-treated patients with type II diabetes mellitus
17. Troglitazone reduces hyperglycaemia and selectively acute phase serum proteins in patients with type 2 diabetes
18. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes
19. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients
20. Effect of troglitazone, a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy
21. The Troglitazone Study Group: Cardiac and glycemic benefits of troglitazone treatment in NIDDM
22. Troglitazone: A review of its use in the management of type 2 diabetes mellitus
23. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
24. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non insulin dependent diabetes
25. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
26. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study
27. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus
28. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus
29. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
30. Troglitazone directly increase HDL cholesterol levels
31. Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance
32. Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone
33. Relationships between apolipoprotein (a) phenotype and increase of lipoprotein (a) by troglitazone
34. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator activated receptor gamma
35. Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase
36. Homeaostasis model assessment: Insulin resistance and B cell function from fasting plasma glucose and insulin concentrations in man
37. Estimation of the concentration of low density lipoproteins cholesterol in plasma without the use of ultracentrifuge
38. Lipid and lipoprotein analysis
39. Particle size and protein content of subfrations of the SF > 20 plasma lipoproteins isolated by density gradient centrifugation
40. American Diabetes Association 60th Scientific Sessions 2000: Thiazolidinediones, obesity and related topics
41. Nonhypoglycemic effects of thiazolidinediones
42. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones
43. Relationship of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction
44. High density lipoproteins and coronary atherosclerosis: A strong inverse relation with the largest particles is confined to normotriglyceridemic patients
45. Thiazolidinediones, dyslipidemia and insulin resistance syndrome
46. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic effect of thiazolidinediones
47. Metabolic basis of hypotriglyceridemic effect of insulin in normal men
48. Apolipoprotein B metabolism and distribution of VLDL and LDL subfractions
49. Metabolism of high density lipoprotein subfractions
50. Tangier disease as a test of the reverse cholesterol transport hypothesis
51. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
52. Regulation of absorption and ABC1 mediated efflux of cholesterol by RXR heterodimers
53. Addition of low dose rosiglitazone to sulphonylurea therapy glycaemic control in type 1 diabetic patients
54. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors
55. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology
56. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor deficient mice
57. Troglitazone's effect on lipoprotein (a) levels
58. Insulin and 2 hour glucose levels are inversely related to Lp(a) concentration controlled for LPA genotype
59. Effect of troglitazone on insulin sensitivity and pancreatic B cell function in women at high risk of NIDDM
60. Treatment with the oral antidiabetic agent troglitazone improve B cell responses to glucose in subjects with impaired glucose tolerance
61. The relation of proinsulin and insulin to insulin sensitivity and acute insulin response in subjects with newly diagnosed type II diabetes: The Insulin Resistance Atherosclerosis Study
62. Reduced beta cell function contributes to impaired glucose tolerance in dogs made obese by high fat feeding
63. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome
64. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus
65. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells
66. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS)